文献速递瓣膜外科

生物瓣主动脉瓣置换术后再干预率:丹麦全国队列研究

Reintervention rates following bioprosthetic surgical aortic valve replacement-a Danish Nationwide Cohort Study.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

结果显示5年再干预率仅3.7/1000人年(≤1.5%),而5年死亡率为21.7/1000人年,再干预中相当比例归因于感染性心内膜炎。

要点

  • 生物瓣主动脉瓣置换术后5年再干预率低,仅3.7/1000人年(≤1.5%)。
  • 5年全因死亡率达21.7/1000人年,竞争风险影响再干预率评估。
  • 再干预中感染性心内膜炎占比高:3年48%、5年37%。

核心结论

  • 生物瓣主动脉瓣置换术后5年内再干预率相对罕见,且相当比例由感染性心内膜炎导致。

主要发现

  • 在90天无再干预生存者中,5年再干预率为3.7/1000人年(≤1.5%),5年全因死亡率为21.7/1000人年。
  • 考虑死亡竞争风险后,5年再干预率与年龄组呈负相关,各年龄组均较低但长期逐渐升高。
  • 再干预中推测因感染性心内膜炎所致者3年占48%、5年占37%。
  • 若每年行经胸超声心动图,前5年每例再干预对应的理论超声检查比为248,排除心内膜炎事件后为425。

关键数值与推荐

  • 5年再干预率3.7/1000人年(≤1.5%),5年死亡率21.7/1000人年。
  • 再干预中感染性心内膜炎占比:3年48%、5年37%。
  • 年度超声与再干预的理论比值:含心内膜炎248,排除后425。

临床怎么用

  • 生物瓣主动脉瓣置换术后早期再干预需求低,可据此优化超声随访资源配置,避免过度检查。
  • 感染性心内膜炎是再干预的重要原因,随访中需关注其预防与识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Updated European guidelines recommend annual echocardiographic evaluation after bioprosthetic surgical aortic valve replacement (bio-SAVR). Given the increased demand on health care resources, only clinically relevant controls can be prioritized. We therefore aimed to explore reintervention rates following bio-SAVR. METHODS: From the nationwide Danish Register of Surgical Procedures, we identified all patients ≥40 years with isolated bio-SAVR ± concomitant coronary artery bypass graft surgery (CABG) during 2000-2016. In 90-day reintervention-free survivors, we assessed aortic valve reintervention rates (primary outcome) and all-cause mortality rates (secondary outcome) at 1, 3 and 5 years with total follow-up until 31 December 2017 and further estimated annual theoretical echocardiographic control visits. RESULTS: In 10 518 patients with bio-SAVR (+CABG 39.7%), we observed low reintervention rates at 1, 3 and 5 years, but with high rates of all-cause mortality; i.e. 5-year reintervention rate of 3.7/1000 person-years (≤1.5%) and 5-year mortality rate of 21.7/1000 person-years. Accounting for the competing risk of death, 5-year rates were inversely related to age group and remained relatively low across all age categories but increased gradually in the long term. A significant proportion of reinterventions were presumed due to infectious endocarditis (48% at 3 years, 37% at 5 years). With annual transthoracic echocardiography, the theoretical ratio of echocardiographies per reintervention in the first 5 years was 248, and 425 when endocarditis events were excluded. CONCLUSION: Reintervention rates within the first 5 years following bio-SAVR were relatively rare, and with a substantial number due to endocarditis.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Schmiegelow MDS, Elming H, Sibilitz KL, et al. Reintervention rates following bioprosthetic surgical aortic valve replacement-a Danish Nationwide Cohort Study. Eur J Cardiothorac Surg. 2022. PMID: 34411227. doi:10.1093/ejcts/ezab365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。